Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 6/20 | 0.60 |
| ▸ | UBA3 | Q8TBC4 | 6/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 11/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15007594 | 0.80 | NAE1 (0.61) | NAE1UBA3S1PR1MEN1KMT2A | |
| SCHEMBL15007593 | 0.77 | NAE1 (0.61) | NAE1UBA3S1PR1MEN1KMT2A | |
| SCHEMBL783481 | 0.75 | NAE1 (1.00) | NAE1UBA3 | |
| SCHEMBL25387099 | 0.65 | NAE1 (0.48) | NAE1UBA3 | |
| SCHEMBL26250382 | 0.65 | NAE1 (0.48) | NAE1UBA3 | |
| SCHEMBL3032942 | 0.65 | S1PR1 (0.58) | S1PR1MEN1KMT2AS1PR5 | |
| SCHEMBL24344306 | 0.64 | KMT2A (0.47) | MEN1KMT2AMAP2K7PRCP | |
| SCHEMBL29535199 | 0.64 | KMT2A (0.47) | MEN1KMT2AMAP2K7PRCP | |
| SCHEMBL2771904 | 0.63 | S1PR1 (0.57) | S1PR1MEN1KMT2AS1PR5 | |
| SCHEMBL31153390 | 0.62 | PRMT5 (0.56) | NAE1UBA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150525-B2 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150183753-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183753-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | RCE1, ECE1, UBE2E1 | NAE1 24/4885UBA3 6/4885S1PR1 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.